Who Owns Prestige Consumer Healthcare Company?

Prestige Consumer Healthcare Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Prestige Consumer Healthcare?

Prestige Consumer Healthcare grew by acquiring and revitalizing OTC brands since 1996, shaping capital allocation and brand focus. Its mix of founder-led strategy and public market discipline drives portfolio decisions and retail execution.

Majority ownership is dispersed among public and institutional investors, with institutional holders and mutual funds holding the largest stakes and the board guiding M&A and brand support. See Prestige Consumer Healthcare Porter's Five Forces Analysis for strategic context.

Founders and early ownership of Prestige Consumer Healthcare trace to a mid-1990s brand-platform build led by Peter Mann and partners, supported by private equity backers; Ronald M. Lombardi joined later and rose to CEO though he is not cited as a founder.

Founding Team

Peter Mann and partners structured the initial OTC brand platform and assembled early management including Mark Pettie and other OTC veterans.

Early Executive Roles

Ronald M. Lombardi later joined the leadership team and ultimately became CEO; he is not listed as an original founder.

Private Equity Sponsorship

Late 1990s and early 2000s private equity funds financed roll-up acquisitions, enabling purchases of legacy OTC brands from larger CPG firms.

Founder Equity

Founders retained minority stakes that diluted through recapitalizations; specific inaugural splits and vesting were privately held and not disclosed in SEC filings.

Standard Vesting

Early arrangements typically followed standard four-year vesting and buy-sell provisions permitting sponsor-led liquidity events as the portfolio scaled.

Transition of Control

As the roll-up matured, founder stakes were converted or bought down, shifting control to institutional sponsors and later to diversified public shareholders after listing.

There were no widely reported founder litigation disputes; control migrated predictably from founding executives to financial sponsors and into the public float as the company expanded.

Key early ownership facts

Founders, PE backers, and later public investors shaped the ownership trajectory; SEC filings for the public company era document institutional stakes but not the original private splits.

• Founding leadership: Peter Mann plus partners; early executives included Mark Pettie and OTC veterans.
• Ronald M. Lombardi: joined later and became CEO; not a founder.
• Early financing: private equity funds in late 1990s/early 2000s funded brand acquisitions and roll-up growth.
• Equity mechanics: private inaugural splits undisclosed; typical four-year vesting and buy-sell clauses applied.

For context on current business lines and how early roll-ups fed revenue profiles see Revenue Streams & Business Model of Prestige Consumer Healthcare

Prestige Consumer Healthcare SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events shaping Prestige Consumer Healthcare ownership include the 2005 NYSE IPO as Prestige Brands Holdings, the 2014–2016 acquisition wave (Insight Pharmaceuticals, DenTek, Fleet’s Summer’s Eve assets) that increased leverage and broadened institutional holders, and the 2021 TheraTears acquisition plus ongoing buybacks and deleveraging that concentrated shares among long-only institutions and index funds.

Current ownership profile shows >90% institutional ownership of the free float, with Vanguard and BlackRock among the largest passive holders and Fidelity, State Street, Dimensional, and Wellington common among active institutions; insiders hold low-single-digit percentages and no controlling shareholder exists.

Ownership Snapshot & Recent Trends

Institutional investors dominate the Prestige Consumer Healthcare ownership landscape; index/ETF giants and active asset managers lead holdings while insider stakes remain small.

• Index/ETF holders: Vanguard and BlackRock typically hold mid-to-high single-digit percentages each
• Active institutions: Fidelity, State Street, Dimensional, Wellington often rank among top ten
• Insider ownership: executives and directors collectively under 5%, CEO beneficial stake 1% or less
• No controlling shareholder; ownership dispersed across long-only funds and ETFs

For historical context and a concise timeline of strategic moves that affected Prestige Consumer Healthcare shareholders, see Brief History of Prestige Consumer Healthcare.

Prestige Consumer Healthcare PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Prestige Consumer Healthcare’s board follows a single-class common stock, one-share-one-vote model and includes the CEO alongside independent directors with CPG, healthcare, retail, finance and M&A backgrounds; governance aligns with NYSE and SEC standards and emphasizes capital allocation discipline.

No director or entity holds special voting rights or founder super-votes; institutional ownership is diversified and no investor is contractually entitled to a board seat by ownership percentage. Shareholder engagement is led by large passive and active institutions with focus on ROIC, leverage targets, and selective M&A filters.

Board composition and voting power highlights

Key governance facts: single-class stock, independent board majority, committee structure matching NYSE/SEC expectations.

• One-share-one-vote common stock; no dual-class or golden shares
• Board chaired by independent directors with consumer and healthcare expertise
• No recent proxy fights or dual-class conversions reported through 2024–2025
• Institutional investors (e.g., large passive funds and active asset managers) drive engagement; top holders typically include major index funds

For context on strategy and brand investment that drive governance debates, see Marketing Strategy of Prestige Consumer Healthcare.

Prestige Consumer Healthcare Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Since 2019, Prestige Consumer Healthcare ownership has trended toward higher institutional concentration, steady buybacks and modest deleveraging, while ownership remains broadly dispersed without a controlling shareholder.

Institutional investors and passive funds now represent the largest shareholder cohort, while retail and insiders together hold the remainder; analysts expect continued emphasis on targeted OTC acquisitions, opportunistic repurchases, and maintenance of a one-share-one-vote public structure.

Institutional ownership

Large passive managers like Vanguard and BlackRock materially increased their combined stake, contributing to an estimated institutional ownership range near 55–65% by 2024–2025.

Capital allocation

Management prioritized deleveraging toward low-2x to sub-3x net leverage while executing repurchases funded by strong free cash flow rather than pursuing large transformational deals.

Ownership structure

Ownership remains dispersed with no majority owner; absence of dual-class stock has reinforced board independence and one-share-one-vote accountability.

Where to find filings

SEC filings (13F, proxy statements and 10-K) provide detailed lists of Prestige Consumer Healthcare major shareholders and changes; see company context in Mission, Vision & Core Values of Prestige Consumer Healthcare.

Prestige Consumer Healthcare Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔